Literature DB >> 11160887

RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors.

C Arnaudeau1, L Rozier, C Cazaux, M Defais, D Jenssen, T Helleday.   

Abstract

The RAD51 protein has been shown to participate in homologous recombination by promoting ATP-dependent homologous pairing and strand transfer reactions. In the present study, we have investigated the possible involvement of RAD51 in non-homologous recombination. We demonstrate that overexpression of CgRAD51 enhances the frequency of spontaneous non-homologous recombination in the hprt gene of Chinese hamster cells. However, the rate of non-homologous recombination induced by the topoisomerase inhibitors campothecin and etoposide was not altered by overexpression of RAD51. These results indicate that the RAD51 protein may perform a function in connection with spontaneous non-homologous recombination that is not essential to or not rate-limiting for non-homologous recombination induced by camptothecin or etoposide. We discuss the possibility that the role played by RAD51 in non-homologous recombination observed here may not be linked to non-homologous end-joining.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160887      PMCID: PMC30407          DOI: 10.1093/nar/29.3.662

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  40 in total

1.  The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells.

Authors:  C Arnaudeau; T Helleday; D Jenssen
Journal:  J Mol Biol       Date:  1999-06-25       Impact factor: 5.469

2.  Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.

Authors:  D Strumberg; A A Pilon; M Smith; R Hickey; L Malkas; Y Pommier
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells.

Authors:  C Arnaudeau; E Tenorio Miranda; D Jenssen; T Helleday
Journal:  Mutat Res       Date:  2000-11-09       Impact factor: 2.433

Review 4.  Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations.

Authors:  P Pfeiffer; W Goedecke; G Obe
Journal:  Mutagenesis       Date:  2000-07       Impact factor: 3.000

5.  Targeted disruption of the Rad51 gene leads to lethality in embryonic mice.

Authors:  T Tsuzuki; Y Fujii; K Sakumi; Y Tominaga; K Nakao; M Sekiguchi; A Matsushiro; Y Yoshimura
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  Induction of RNA-stabilized DNA conformers by transcription of an immunoglobulin switch region.

Authors:  M E Reaban; J A Griffin
Journal:  Nature       Date:  1990-11-22       Impact factor: 49.962

7.  Gene targeting is enhanced in human cells overexpressing hRAD51.

Authors:  R J Yáñez; A C Porter
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

Review 8.  DNA double strand break repair in mammalian cells.

Authors:  P Karran
Journal:  Curr Opin Genet Dev       Date:  2000-04       Impact factor: 5.578

9.  Binding of inositol phosphate to DNA-PK and stimulation of double-strand break repair.

Authors:  L A Hanakahi; M Bartlet-Jones; C Chappell; D Pappin; S C West
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

10.  Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes.

Authors:  R G Shao; C X Cao; H Zhang; K W Kohn; M S Wold; Y Pommier
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

View more
  8 in total

Review 1.  The consequences of Rad51 overexpression for normal and tumor cells.

Authors:  Hannah L Klein
Journal:  DNA Repair (Amst)       Date:  2008-02-01

2.  Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment.

Authors:  Yiduo Hu; Xincheng Lu; Guangjin Zhou; Ellen L Barnes; Guangbin Luo
Journal:  Mol Biol Cell       Date:  2008-11-05       Impact factor: 4.138

3.  Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells.

Authors:  Cecilia Lundin; Klaus Erixon; Catherine Arnaudeau; Niklas Schultz; Dag Jenssen; Mark Meuth; Thomas Helleday
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

4.  Camptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination.

Authors:  Luciana Ferrara; Eric B Kmiec
Journal:  Nucleic Acids Res       Date:  2004-10-05       Impact factor: 16.971

5.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

6.  DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair.

Authors:  Songmin Ying; Zhihui Chen; Annette L Medhurst; Jessica A Neal; Zhengqiang Bao; Oliver Mortusewicz; Joanna McGouran; Xinming Song; Huahao Shen; Freddie C Hamdy; Benedikt M Kessler; Katheryn Meek; Thomas Helleday
Journal:  Cancer Res       Date:  2015-11-24       Impact factor: 12.701

Review 7.  The Werner syndrome protein: linking the replication checkpoint response to genome stability.

Authors:  Pietro Pichierri; Francesca Ammazzalorso; Margherita Bignami; Annapaola Franchitto
Journal:  Aging (Albany NY)       Date:  2011-03       Impact factor: 5.682

Review 8.  PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.

Authors:  Nannan Wang; Yan Yang; Dongdong Jin; Zhenan Zhang; Ke Shen; Jing Yang; Huanhuan Chen; Xinyue Zhao; Li Yang; Huaiwu Lu
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.